OUTLOOK THERAPEUTICS INC (OTLK) Stock Forecast & Price Target
OUTLOOK THERAPEUTICS INC · NASDAQ
$0.90-0.17 (-15.77%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering OUTLOOK THERAPEUTICS INC, 1 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $0.50 to $10.00 (about 20.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.83 sits 327% above the current $0.90. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy120%
Hold480%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to OUTLOOK THERAPEUTICS INC.
As of Jul, 1 of 5 firms rate OTLK a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OTLK EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.10 – $-0.05 · 3 analysts · -72% YoY
Next period, 3 analysts expect OUTLOOK THERAPEUTICS INC to earn $-0.08 a share (range $-0.10 – $-0.05), versus $-0.29 a year earlier. Full-year consensus is $-0.51, growing to $-0.22 the year after.
REVENUE · NEXT QUARTER
$2.6M
Range $2.6M – $2.6M · 3 analysts
Revenue is expected to reach $2.6M (range $2.6M – $2.6M). Full-year consensus is $2.0M, rising to $56.3M next year.
Top analysts covering OUTLOOK THERAPEUTICS INC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OTLK.
#1
Daniil Gataulin
Chardan Capital · Rank #36
Hold
$1.00+11.5% to target
Overall win rate
55%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #212
Hold
$0.50-44.3% to target
Overall win rate
35%
+ Follow
#3
Edward Woo
Ascendiant Capital · Rank #358
Buy
$10.00+1014.7% to target
Overall win rate
26%
+ Follow
#4
EH
Eddie Hickman
Guggenheim
Hold
No targeton OTLK
Coverage
—
+ Follow
#5
Julian Harrison
BTIG
Hold
No targeton OTLK
Coverage
—
+ Follow
OTLK stock forecast FAQ
What is OTLK's average 12-month price target?+
The 3 analysts with a live target average $3.83 for OUTLOOK THERAPEUTICS INC over the next 12 months, ranging from a $10.00 high to a $0.50 low.
Is OTLK stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 1 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for OTLK?+
The Street-high target is $10.00 (Ascendiant Capital), and the Street-low is $0.50 (HC Wainwright & Co.). The average of all 3 active targets is $3.83.
How many Wall Street analysts cover OTLK?+
5 analysts have an active rating on OUTLOOK THERAPEUTICS INC, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering OTLK?+
Among analysts who currently cover OTLK, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #36). Their current call is Hold with a $1.00 target.
What is OUTLOOK THERAPEUTICS INC's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.10 – $-0.05) across 3 analysts. Full-year EPS is projected at $-0.51, rising to $-0.22 the following year.
How much revenue is OUTLOOK THERAPEUTICS INC expected to report next quarter?+
Consensus revenue is $2.6M (range $2.6M – $2.6M). Full-year revenue is projected at $2.0M, growing to $56.3M next year.
Have analysts been upgrading or downgrading OTLK lately?+
As of Jul, 1 of 5 firms rate OTLK a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OTLK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
